Pharmacotherapy of depersonalization/derealization disorder
- Daphne Simeon, MD
Daphne Simeon, MD
- Associate Clinical Professor
- Mount Sinai School of Medicine
Depersonalization/derealization disorder (DDD) is characterized by persistent or recurrent depersonalization and/or derealization that causes clinically significant distress, while reality testing remains intact .
DDD has a prevalence of approximately 2 percent and is associated with significant morbidity, but often goes undetected or misdiagnosed, leading to delays in treatment.
This topic discusses pharmacotherapy for DDD. The epidemiology, pathogenesis, clinical manifestations, course, and diagnosis of DDD are discussed separately. Psychotherapy for DDD is also discussed separately. (See "Depersonalization/derealization disorder: Epidemiology, pathogenesis, clinical manifestations, course, and diagnosis" and "Psychotherapy of depersonalization/derealization disorder".)
APPROACH TO TREATMENT
Our approach to selecting among treatments for depersonalization/derealization disorder, including the use of pharmacotherapy and psychotherapy, is discussed separately. (See "Approach to treating depersonalization/derealization disorder".)
Depersonalization — Depersonalization is a persistent or recurrent feeling of detachment or estrangement from one’s self. An individual experiencing depersonalization may report feeling like an automaton or as if in a dream or as if watching himself or herself in a movie. Depersonalized individuals may report the sense of being an outside observer of their mental processes or their body. They often report feeling a loss of control over their thoughts, perceptions, and actions.To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, Arlington 2013.
- Simeon D, Knutelska M, Nelson D, Guralnik O. Feeling unreal: a depersonalization disorder update of 117 cases. J Clin Psychiatry 2003; 64:990.
- Simeon D, Guralnik O, Schmeidler J, Knutelska M. Fluoxetine therapy in depersonalisation disorder: randomised controlled trial. Br J Psychiatry 2004; 185:31.
- Simeon D, Stein DJ, Hollander E. Treatment of depersonalization disorder with clomipramine. Biol Psychiatry 1998; 44:302.
- Simeon D, Knutelska M. An open trial of naltrexone in the treatment of depersonalization disorder. J Clin Psychopharmacol 2005; 25:267.
- Aliyev NA, Aliyev ZN. Lamotrigine in the immediate treatment of outpatients with depersonalization disorder without psychiatric comorbidity: randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2011; 31:61.
- Sierra M, Phillips ML, Lambert MV, et al. Lamotrigine in the treatment of depersonalization disorder. J Clin Psychiatry 2001; 62:826.
- Sierra M, Phillips ML, Ivin G, et al. A placebo-controlled, cross-over trial of lamotrigine in depersonalization disorder. J Psychopharmacol 2003; 17:103.
- Uguz F, Sahingoz M. Aripiprazole in depersonalization disorder comorbid with major depression and obsessive-compulsive disorder: 3 cases. Clin Neuropharmacol 2014; 37:125.
- Mantovani A, Simeon D, Urban N, et al. Temporo-parietal junction stimulation in the treatment of depersonalization disorder. Psychiatry Res 2011; 186:138.
- Jay EL, Nestler S, Sierra M, et al. Ventrolateral prefrontal cortex repetitive transcranial magnetic stimulation in the treatment of depersonalization disorder: A consecutive case series. Psychiatry Res 2016; 240:118.
- APPROACH TO TREATMENT
- OVERVIEW OF PHARMACOTHERAPY
- SEROTONIN REUPTAKE INHIBITORS
- Side effects
- Side effects
- ANTIPSYCHOTIC MEDICATIONS
- OTHER INTERVENTIONS
- SUMMARY AND RECOMMENDATIONS